Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905401 | 0.98 | TSHR (0.66) | TSHREPHX2ADRA1APRMT1RECQL | |
| SCHEMBL28440634 | 0.98 | TSHR (0.64) | TSHREPHX2ADRA1APRMT1RECQL | |
| SCHEMBL13376980 | 0.93 | RECQL (0.61) | TSHREPHX2RECQLLMNACASP2 | |
| SCHEMBL2771342 | 0.91 | RECQL (0.63) | TSHREPHX2RECQLLMNACASP2 | |
| SCHEMBL13405232 | 0.89 | TSHR (0.53) | TSHREPHX2ADRA1APRMT1RECQL | |
| SCHEMBL16620817 | 0.89 | RECQL (0.61) | TSHREPHX2RECQLLMNACASP2 | |
| SCHEMBL15399777 | 0.87 | TSHR (0.65) | TSHREPHX2RECQLLMNACASP2 | |
| SCHEMBL24483715 | 0.87 | PRMT1 (0.71) | TSHREPHX2ADRA1APRMT1KDM4E | |
| SCHEMBL8766161 | 0.87 | PRMT1 (0.71) | TSHREPHX2ADRA1APRMT1KDM4E | |
| SCHEMBL22506195 | 0.87 | PRMT1 (0.71) | TSHREPHX2ADRA1APRMT1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210047338-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-02-18 | — | — | US | disclosed |
| US-20210047338-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-02-18 | — | — | US | disclosed |
| US-10654864-B2 | Modified cytotoxins and their therapeutic use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-05-19 | — | — | US | disclosed |
| US-10654864-B2 | Modified cytotoxins and their therapeutic use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-05-19 | — | — | US | disclosed |
| US-10286079-B2 | Modified cytotoxins and their therapeutic use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-14 | — | — | US | disclosed |
| US-10286079-B2 | Modified cytotoxins and their therapeutic use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180222915-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180222915-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180222915-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | US | disclosed |
| EP-3353159-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | The Regents of The University of California (US) | 2018-08-01 | — | — | EP | disclosed |
| US-10023581-B2 | Modified cytotoxins and their therapeutic use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023581-B2 | Modified cytotoxins and their therapeutic use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023581-B2 | Modified cytotoxins and their therapeutic use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180000951-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-01-04 | — | — | US | disclosed |
| US-20180000951-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-01-04 | — | — | US | disclosed |
| WO-2017053391-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017053391-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-30 | — | — | WO | disclosed |
| US-20170080094-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170080094-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170080094-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023581-B2 | Modified cytotoxins and their therapeutic use | ANXA5, TP53, FABP1 | TSHR 4093/4885EPHX2 2868/4885ADRA1A 4113/4885 |
| US-10286079-B2 | Modified cytotoxins and their therapeutic use | ANXA5, TP53, FABP1 | TSHR 4093/4885EPHX2 2868/4885ADRA1A 4113/4885 |
| US-20180222915-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | ANXA5, TP53, FABP1 | TSHR 4093/4885EPHX2 2868/4885ADRA1A 4113/4885 |
| US-20180000951-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | ANXA5, TP53, FABP1 | TSHR 4093/4885EPHX2 2868/4885ADRA1A 4113/4885 |
| US-20210047338-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | ANXA5, TP53, FABP1 | TSHR 4093/4885EPHX2 2868/4885ADRA1A 4113/4885 |
| US-20170080094-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | ANXA5, TP53, FABP1 | TSHR 4093/4885EPHX2 2868/4885ADRA1A 4113/4885 |
| US-10654864-B2 | Modified cytotoxins and their therapeutic use | ANXA5, TP53, FABP1 | TSHR 4093/4885EPHX2 2868/4885ADRA1A 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.